The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza
Open accessAbstract
UNLABELLED: The recent swine H1N1 influenza outbreak demonstrated that egg-based vaccine manufacturing has an Achille's heel: its inability to provide a large number of doses quickly. Using a novel manufacturing platform based on transient expression of influenza surface glycoproteins in Nicotiana benthamiana, we have recently demonstrated that a candidate Virus-Like Particle (VLP) vaccine can be generated within 3 weeks of release of sequence information. Herein we report that alum-adjuvanted plant-made VLPs containing the hemagglutinin (HA) protein of H5N1 influenza (A/Indonesia/5/05) can induce cross-reactive antibodies in ferrets. Even low doses of this vaccine prevented pathology and reduced viral loads following heterotypic lethal challenge. We further report on safety and immunogenicity from a Phase I clinical study of the plant-made H5 VLP vaccine in healthy adults 18-60 years of age who received 2 doses 21 days apart of 5, 10 or 20 µg of alum-adjuvanted H5 VLP vaccine or placebo (alum). The vaccine was well tolerated at all doses. Adverse events (AE) were mild-to-moderate and self-limited. Pain at the injection site was the most frequent AE, reported in 70% of vaccinated subjects versus 50% of the placebo recipients. No allergic reactions were reported and the plant-made vaccine did not significantly increase the level of naturally occurring serum antibodies to plant-specific sugar moieties. The immunogenicity of the H5 VLP vaccine was evaluated by Hemagglutination-Inhibition (HI), Single Radial Hemolysis (SRH) and MicroNeutralisation (MN). Results from these three assays were highly correlated and showed similar trends across doses. There was a clear dose-response in all measures of immunogenicity and almost 96% of those in the higher dose groups (2 × 10 or 20 µg) mounted detectable MN responses. Evidence of striking cross-protection in ferrets combined with a good safety profile and promising immunogenicity in humans suggest that plant-based VLP vaccines should be further evaluated for use in pre-pandemic or pandemic situations. TRIAL REGISTRATION: ClinicalTrials.gov NCT00984945.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
Rowe, T., Abernathy, R. A., Hu-Primmer, J., Thompson, W. W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 811
WHO Manual on Animal Influenza Diagnosis and Surveillance
Manu, U. (2002) · Cited by 628
Bresson, J.-L., Perronne, C., Launay, O., Gerdil, C., Saville, M., Wood, J., Höschler, K., & Zambon, M. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68656-x · Cited by 411
The Role of Protein Glycosylation in Allergy
Altmann, F. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000096114 · Cited by 393
Coudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., & Ecochard, R. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-18 · Cited by 374
D’Aoust, M., Couture, M. M. ‐., Charland, N., Trépanier, S., Landry, N., Ors, F., & Vézina, L. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2009.00496.x · Cited by 371
Self-citationBardor, M. (2003) · Glycobiology · doi:10.1093/glycob/cwg024 · Cited by 334
D’Aoust, M., Lavoie, P., Couture, M. M. ‐., Trépanier, S., Guay, J., Dargis, M., Mongrand, S., Landry, N., Ward, B. J., & Vézina, L. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00384.x · Cited by 279
Self-citationImmunogenicity and protective efficacy of influenza vaccination
Hannoun, C., Megas, F., & Piercy, J. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.025 · Cited by 260
Cited by
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Van Hoeven, N., Fox, C. B., Granger, B., Evers, T., Joshi, S. W., Nana, G. I., Evans, S. C., Lin, S., Liang, H., Liang, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46426 · Cited by 87
Metadata
- Authors
- Landry, N., Ward, B. J., Trépanier, S., Montomoli, E., Dargis, M., Lapini, G., & Vézina, L.-P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15559
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2017076506
- Cited by
- 281
- References
- 19
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza. https://app.cochat.ai/papers/10.1371/journal.pone.0015559
- The paper
- Landry, N., Ward, B. J., Trépanier, S., Montomoli, E., Dargis, M., Lapini, G., & Vézina, L.-P. (2010). Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza. PLoS ONE. https://doi.org/10.1371/journal.pone.0015559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.